{"disease":{"id":"bpdcn","name":"bpdcn"},"drugs":{"marketed":[{"drug_id":"tagraxofusp","indication_name":"Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Molecule 129","generic_name":"TAGRAXOFUSP","company_name":"Stemline Therapeeutics Inc","drug_phase":"marketed","molecular_target":"Elongation factor 2","drug_class":"CD123 Interaction [EPC]","quality_score":10,"revenue":null,"mechanism":"Tagraxofusp works by binding to CD123 on cancer cells, causing them to die."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04318678","title":"CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":108,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT07523555","title":"Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":96,"lead_sponsor_name":"Beijing Biotech","has_results":false},{"nct_id":"NCT05476770","title":"Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"Therapeutic Advances in Childhood Leukemia Consortium","has_results":false},{"nct_id":"NCT06006403","title":"Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Chongqing Precision Biotech Co., Ltd","has_results":false},{"nct_id":"NCT07007052","title":"Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":33,"lead_sponsor_name":"French Innovative Leukemia Organisation","has_results":false},{"nct_id":"NCT06690827","title":"Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or BPDCN","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Chongqing Precision Biotech Co., Ltd","has_results":false},{"nct_id":"NCT06765876","title":"CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"Institute of Hematology and Blood Transfusion, Czech Republic","has_results":false},{"nct_id":"NCT04109482","title":"Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Mustang Bio","has_results":false},{"nct_id":"NCT05645744","title":"Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.","phase":"","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Mustang Bio","has_results":false},{"nct_id":"NCT03203369","title":"Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Cellectis S.A.","has_results":false}],"total":10},"guidelines":[],"source":"Drug Landscape verified database"}